X
Xiangpeng Dai
Researcher at Beth Israel Deaconess Medical Center
Publications - 33
Citations - 2408
Xiangpeng Dai is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Ubiquitin ligase & SPOP. The author has an hindex of 21, co-authored 33 publications receiving 1740 citations. Previous affiliations of Xiangpeng Dai include Harvard University & Jilin University.
Papers
More filters
Journal ArticleDOI
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Jinfang Zhang,Xia Bu,Haizhen Wang,Yasheng Zhu,Yan Geng,Naoe Taira Nihira,Yuyong Tan,Yuyong Tan,Yanpeng Ci,Yanpeng Ci,Fei Wu,Fei Wu,Xiangpeng Dai,Jianping Guo,Yu Han Huang,Caoqi Fan,Caoqi Fan,Shancheng Ren,Yinghao Sun,Gordon J. Freeman,Piotr Sicinski,Wenyi Wei +21 more
TL;DR: It is shown that PD-L1 protein abundance is regulated by cyclin D–CDK4 and the cullin 3–SPOP E3 ligase via proteasome-mediated degradation, which reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1–PD-L 1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
Journal ArticleDOI
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Xiangpeng Dai,Wenjian Gan,Xiaoning Li,Xiaoning Li,Shangqian Wang,Wei Zhang,Ling Huang,Shengwu Liu,Qing Zhong,Jianping Guo,Jinfang Zhang,Ting Chen,Kouhei Shimizu,Francisco Beca,Mirjam Blattner,Divya Vasudevan,Dennis L. Buckley,Jun Qi,Lorenz Buser,Pengda Liu,Hiroyuki Inuzuka,Andrew H. Beck,Liewei Wang,Peter J. Wild,Levi A. Garraway,Mark A. Rubin,Christopher E. Barbieri,Kwok-Kin Wong,Senthil K. Muthuswamy,Jiaoti Huang,Yu Chen,James E. Bradner,Wenyi Wei +32 more
TL;DR: The results elucidate the tumor-suppressor role of SPOP in prostate cancer in which it acts as a negative regulator of BET protein stability and also provide a molecular mechanism for resistance to BET inhibitors in individuals with prostate cancer bearing SPOP mutations.
Journal ArticleDOI
SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression
Wenjian Gan,Xiangpeng Dai,Andrea Lunardi,Zhen Li,Hiroyuki Inuzuka,Pengda Liu,Shoreh Varmeh,Jinfang Zhang,Liang Cheng,Yin Sun,John M. Asara,Andrew H. Beck,Jiaoti Huang,Pier Paolo Pandolfi,Wenyi Wei +14 more
TL;DR: In this paper, the Cullin 3-based ubiquitin ligase SPOP was found to be a tumor suppressor to negatively regulate the stability of ERG oncoprotein in prostate cancer, and the SPOP/ERG interaction was modulated by CKI-mediated phosphorylation.
Journal ArticleDOI
Targeting the ubiquitin pathway for cancer treatment.
TL;DR: This review highlighted the critical components along the ubiquitin pathway including E1, E2, various E3 enzymes and DUBs that could serve as potential drug targets and also described the available bioactive compounds that target the ubiqu itin pathway to control various cancers.
Journal ArticleDOI
Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
Lixin Wan,Kexin Xu,Kexin Xu,Yongkun Wei,Jinfang Zhang,Tao Han,Christopher J Fry,Zhao Zhang,Yao Vickie Wang,Li-Yu Huang,Li-Yu Huang,Min Yuan,Weiya Xia,Wei Chao Chang,Wen Chien Huang,Chien Liang Liu,Yuan Ching Chang,Jinsong Liu,Yun Wu,Victor X. Jin,Xiangpeng Dai,Jianfeng Guo,Jianfeng Guo,Jia Liu,Jia Liu,Shulong Jiang,Jin Li,John M. Asara,Myles Brown,Myles Brown,Mien Chie Hung,Mien Chie Hung,Wenyi Wei +32 more
TL;DR: It is reported that AMPK phosphorylates the histone methyltransferase EZH2 at T311 to disrupt the interaction between EZh2 and SUZ12, another core component of the polycomb repressive complex 2 (PRC2), leading to attenuated PRC2-dependent methylation of histone H3 at Lys27.